GlassScriptPhysician profile
David Kukafka
NPI 1255301180
$1,472.12
in general payments reported to CMS, 2019-2025
11 companies · $54.24 in 2025
The $54.24 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.03 · 2020: $101 · 2021: $11.92 · 2022: $45.10 · 2023: $301 · 2024: $871 · 2025: $54.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Travel and Lodging: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.96 |
| Travel and Lodging | $602.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $892.58 | 2024-2025 | Inspire |
| Intuitive Surgical, INC. | $172.24 | 2023 | Da Vinci Surgical System |
| Zoll Respicardia, INC. | $129.11 | 2023 | Remede System |
| Resmed Corp | $91.02 | 2019-2020 | |
| Harmony Biosciences LLC | $68.02 | 2020-2022 | |
| Axsome Therapeutics, INC. | $32.35 | 2025 | Sunosi |
| Glaxosmithkline, LLC. | $21.54 | 2020 | |
| Sunovion Pharmaceuticals INC. | $21.17 | 2020 | |
| Mylan Specialty L.P. | $19.90 | 2020 | |
| Circassia INC. | $12.27 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kukafka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.